Rapid early remission in a patient with severe aplastic anemia: a case report of hetrombopag, cyclosporine, and danazol combination therapy
Severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome that is caused primarily by immune-mediated destruction of hematopoietic stem cells. Traditional treatment relies on immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine (CSA). However, the...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1609771/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849225244227665920 |
|---|---|
| author | Yuting Dai Qiang Guo Xiaoxiao Guo Qiuju Liu |
| author_facet | Yuting Dai Qiang Guo Xiaoxiao Guo Qiuju Liu |
| author_sort | Yuting Dai |
| collection | DOAJ |
| description | Severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome that is caused primarily by immune-mediated destruction of hematopoietic stem cells. Traditional treatment relies on immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine (CSA). However, the toxicity and limited availability of ATG have spurred interest in ATG-free regimens. This case report describes a 28-year-old male with SAA who was treated with a combination of CSA, danazol, and hetrombopag (HPAG). The patient presented with pancytopenia and a hypocellular bone marrow, thus meeting the SAA criteria. He received CSA (5 mg/kg/day), HPAG (started at 10 mg and increased to 15 mg/day), and danazol (400 mg/day). Hematologic assessments using the NIH criteria revealed a partial response at 3 months and a complete response at 6 months, with reduced proportions of active T-cell subclones and no severe adverse events. This case suggests that the combination of CSA, HPAG, and danazol is effective in treating SAA, and a large-scale clinical trial is warranted to further confirm these promising results. |
| format | Article |
| id | doaj-art-47565bd6e26347cd8b50a69eb3797ac4 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-47565bd6e26347cd8b50a69eb3797ac42025-08-25T05:25:42ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-08-011610.3389/fimmu.2025.16097711609771Rapid early remission in a patient with severe aplastic anemia: a case report of hetrombopag, cyclosporine, and danazol combination therapyYuting DaiQiang GuoXiaoxiao GuoQiuju LiuSevere aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome that is caused primarily by immune-mediated destruction of hematopoietic stem cells. Traditional treatment relies on immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine (CSA). However, the toxicity and limited availability of ATG have spurred interest in ATG-free regimens. This case report describes a 28-year-old male with SAA who was treated with a combination of CSA, danazol, and hetrombopag (HPAG). The patient presented with pancytopenia and a hypocellular bone marrow, thus meeting the SAA criteria. He received CSA (5 mg/kg/day), HPAG (started at 10 mg and increased to 15 mg/day), and danazol (400 mg/day). Hematologic assessments using the NIH criteria revealed a partial response at 3 months and a complete response at 6 months, with reduced proportions of active T-cell subclones and no severe adverse events. This case suggests that the combination of CSA, HPAG, and danazol is effective in treating SAA, and a large-scale clinical trial is warranted to further confirm these promising results.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1609771/fullsevere aplastic anemiacase reportimmunosupressive agentsantithymocyte globulincyclosporinehetrombopag |
| spellingShingle | Yuting Dai Qiang Guo Xiaoxiao Guo Qiuju Liu Rapid early remission in a patient with severe aplastic anemia: a case report of hetrombopag, cyclosporine, and danazol combination therapy Frontiers in Immunology severe aplastic anemia case report immunosupressive agents antithymocyte globulin cyclosporine hetrombopag |
| title | Rapid early remission in a patient with severe aplastic anemia: a case report of hetrombopag, cyclosporine, and danazol combination therapy |
| title_full | Rapid early remission in a patient with severe aplastic anemia: a case report of hetrombopag, cyclosporine, and danazol combination therapy |
| title_fullStr | Rapid early remission in a patient with severe aplastic anemia: a case report of hetrombopag, cyclosporine, and danazol combination therapy |
| title_full_unstemmed | Rapid early remission in a patient with severe aplastic anemia: a case report of hetrombopag, cyclosporine, and danazol combination therapy |
| title_short | Rapid early remission in a patient with severe aplastic anemia: a case report of hetrombopag, cyclosporine, and danazol combination therapy |
| title_sort | rapid early remission in a patient with severe aplastic anemia a case report of hetrombopag cyclosporine and danazol combination therapy |
| topic | severe aplastic anemia case report immunosupressive agents antithymocyte globulin cyclosporine hetrombopag |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1609771/full |
| work_keys_str_mv | AT yutingdai rapidearlyremissioninapatientwithsevereaplasticanemiaacasereportofhetrombopagcyclosporineanddanazolcombinationtherapy AT qiangguo rapidearlyremissioninapatientwithsevereaplasticanemiaacasereportofhetrombopagcyclosporineanddanazolcombinationtherapy AT xiaoxiaoguo rapidearlyremissioninapatientwithsevereaplasticanemiaacasereportofhetrombopagcyclosporineanddanazolcombinationtherapy AT qiujuliu rapidearlyremissioninapatientwithsevereaplasticanemiaacasereportofhetrombopagcyclosporineanddanazolcombinationtherapy |